Dihydrotestosterone News and Research

RSS

Dihydrotestosterone (DHT) is a biologically active metabolite of the hormone testosterone, formed primarily in the prostate gland, testes, hair follicles, and adrenal glands

Androgen receptor in prostate cancer cells can activate different gene set when bound to antiandrogens

The androgen receptor in prostate cancer cells can activate different sets of genes depending on whether it binds with an androgen hormone or an antiandrogen drug, according to a new study led by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.

28 Jan 2015

Low levels of testosterone decline physical function in elderly men

Elderly men with low levels of testosterone or other sex hormones have twice the likelihood of having declining physical function over two years' time compared with their peers who have the highest hormone levels, a new study from Australia finds.

23 Jun 2014

Clinical data of cabozantinib to be presented at ASCO meeting

Exelixis, Inc. announced today that cabozantinib will be the subject of nine separate data presentations at the upcoming 2013 Annual Meeting of the American Society of Clinical Oncology.

8 May 2013

Abiraterone's anti-androgenic properties may stop tumor growth of CRPC, says prize-winning Dutch study

As part of an EU-supported IMI-PREDECT consortium, a Dutch study showed that anti-androgenic properties of the drug abiraterone may provide an additional mechanism of action in blocking tumour growth of castration resistant prostate cancer (CRPC).

16 Mar 2013

Prostate tissue androgen content predicts ADT outcome

Determining the androgen content in prostate tissue could predict patients’ responses to androgen deprivation therapy and the risk for castration-resistant prostate cancer, show study findings.

6 Mar 2013

Prediagnostic androgen level not linked to prostate cancer outcome

Low prediagnostic levels of circulating sex hormones are not associated with more aggressive disease in patients with prostate cancer, say US researchers.

28 Jan 2013

Clear link between androgenetic alopecia and benign prostate hyperplasia

Spanish scientists have confirmed that there is a clear relationship between androgenetic alopecia (common premature baldness) and benign prostate hyperplasia (BPH), a benign enlargement of the prostate that appears in aging men and is associated with certain hormones as dihydrotestosterone. This condition appears in 50% of men over 60 year old and causes voiding syndrome i.e. urinary frequency.

16 Mar 2012

KSU professor turns to nutrition to tackle prostate cancer

A Kansas State University professor is turning to nutrition to tackle prostate cancer. Brian Lindshield, assistant professor of human nutrition, is helping men make more informed diet decisions by studying foods and dietary supplements that may reduce the risk of prostate cancer. Prostate cancer is one of the most common forms of cancer among men in the United States.

24 Jan 2012

5a-reductase inhibitors for male health problems can affect sexual health

A new study published in The Journal of Sexual Medicine reveals that, for the first time, 5a-reductase inhibitors commonly used to treat urinary problems in patients with benign prostatic hyperplasia (BPH) and found in popular medications to treat hair loss, can produce, persistent erectile dysfunction (ED), depression and loss of libido, even after the medication has been discontinued.

7 Mar 2011

Men going bald at young age more likely to develop prostate cancer in later life

Men who start to lose hair at the age of 20 are more likely to develop prostate cancer in later life and might benefit from screening for the disease, according to a new study published online in the cancer journal, Annals of Oncology today.

15 Feb 2011

New book on fighting hair loss

World renowned hair loss expert, Dr. Larry Shapiro, announced the release of his new book, Fight Hair Loss and Win! and says that Elin Nordegren is not alone when it comes to hair loss as a result of stress. Shapiro says millions of women and men are experiencing the same and that heightened levels of stress, popular nutritional supplements, hormonal imbalances and many other unsuspecting factors are now linked to hair loss.

26 Aug 2010

SPET-085 is effective in blocking critical enzyme that leads to BPH: Study

A new study, published in the July issue of Advances in Therapy, revealed that a novel saw palmetto extract, SPET-085, is as effective as finasteride, the standard prescription drug therapy, in blocking the critical enzyme that leads to benign prostatic hyperplasia.

13 Jul 2010

Prevention, awareness of enlarged prostate can help save lives

We live in a country of excess where size often matters most. Supersize, grande, max, king size - but is bigger always better? Certainly not when it comes to male health and an enlarged prostate.

16 Jun 2010

REDUCE trial data published in the online version of European Urology

On 8 May an editorial about the Reduction by Dutasteride of Prostate Cancer Events trial by Fritz H. Schröder and Monique J. Roobol was published in the online version of European Urology, the scientific journal of the European Association of Urology.

25 May 2010

Harbor BioSciences announces presentation of new data from Apoptone Phase I/IIa trial at ASCO Annual Meeting

Harbor BioSciences, Inc. today announced that new data from the Phase I/IIa clinical trial of the company's lead drug candidate Apoptone®, its anticancer drug candidate being developed for prostate cancer, will be presented as part of the Scientific Program in a General Poster Session at the American Society of Clinical Oncology (ASCO) Annual Meeting.

18 May 2010

International, four-year study finds dutasteride reduces risk of prostate cancer diagnosis in men

A drug already prescribed to shrink benign, enlarged prostates has been shown to reduce the risk of a prostate cancer diagnosis by 23 percent in men with an increased risk of the disease, a large international trial has found. Results are reported April 1 in the New England Journal of Medicine.

2 Apr 2010

Harbor BioSciences to receive patent for Apoptone in treatment of prostate cancer, breast cancer and benign prostatic hypertrophy

Harbor BioSciences, Inc. today announced that the company has received a notice of allowance from the United States Patent Office of patent claims covering the use of its lead product candidate Apoptone®. The patent claims cover the use of Apoptone to treat prostate cancer, breast cancer and benign prostatic hypertrophy. Apoptone (HE3235) is a novel synthetic steroid analog of a dihydrotestosterone metabolite and has been found to stimulate cell death (apoptosis) in animal models of prostate and breast cancers.

25 Feb 2010

Interim data from Hollis-Eden Pharmaceuticals' Apoptone Phase I/II clinical trial presented

Hollis-Eden Pharmaceuticals, Inc., today reported preliminary results of its ongoing Phase I/II clinical trial with Apoptone® (HE3235) for hormone-resistant prostate cancer (also called castrate-resistant prostate cancer or CRPC). Presented at the Molecular Targets and Cancer Therapeutics Conference, which is co-sponsored by the AACR, NCI and EORTC, the poster is titled: "Results of preclinical and clinical Phase I/II open-label dose-ranging trial with HE3235, a synthetic adrenal hormone, in Castrate Resistant Prostate Cancer (CRPC)."

16 Nov 2009

Acrux reports Phase III trial results evaluating AXIRON for testosterone deficiency

Australian company, Acrux, today announced positive results from a Phase III trial evaluating the safety and efficacy of AXIRON™ in 155 men with testosterone deficiency (hypogonadism), across 26 sites in six countries.

29 Sep 2009

New therapy for metastatic prostate cancer shows promise

A new therapy for metastatic prostate cancer has shown considerable promise in early clinical trials involving patients whose disease has become resistant to current drugs.

12 Apr 2009